Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]

Artificial intelligence-enabled electrocardiography for detection of left ventricular diastolic dysfunction: a systematic review and meta-analysis

Edjimbi J, Shah N, Donisi L, Gajjar A, See C, Grimshaw AA, Diop HB, Ribeiro ALP, Marijon E, Clifford G, Gaye B. Artificial intelligence-enabled electrocardiography[...]

Heart failure among people with HIV: prescription of guideline-directed medical therapy

Cutshaw MK, Clare R, Chiswell K, Hofmann P, Pettit AC, Meissner E, Durstenfeld MS, Longenecker CT, Bloomfield GS, Okeke NL. Heart failure among people with[...]